Russia to Launch Free Enteromix Cancer Vaccine Using mRNA Technology in 2025, Aiming for 75-80% Tumor Reduction

Dec 17, 2024, 10:01 PM

Russia's Ministry of Health has announced the development of a personalized cancer vaccine, named Enteromix, which is set to be distributed free of charge to patients starting in early 2025. The vaccine, developed by the Radiology Medical Research Center of the Russian Ministry of Health, utilizes mRNA technology and is designed to treat cancer patients rather than prevent cancer in the general public. Andrey Kaprin, the General Director of the center, stated that the vaccine will be tailored to each patient's specific needs and is expected to reduce tumor size by 75-80%. The vaccine's development has been supported by preclinical trials showing its ability to suppress tumor growth and prevent cancer spread, according to Alexander Gintsburg, Director of the Gamaleya National Research Center for Epidemiology and Microbiology. The cost to the state for each dose is estimated at 300,000 rubles, but it will be provided free to citizens. Clinical trials for the vaccine are expected to begin in late 2024 or early 2025, focusing on patients aged 18 to 75 with histologically confirmed tumors who have exhausted all other treatment options.